Synthesis and biological evaluation of novel N9-heterobivalent β-carbolines as angiogenesis inhibitors
A series of novel N9-heterobivalent β-carbolines has been synthesized. All the novel compounds were tested for their anticancer activity against six tumour cell lines in vitro. Among these molecules, compounds 5b, and 5w exhibited strong cytotoxic activities with IC50 value of lower than 20 μM. Acut...
Saved in:
Main Authors: | Liang Guo (Author), Qin Ma (Author), Wei Chen (Author), Wenxi Fan (Author), Jie Zhang (Author), Bin Dai (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2019-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Inhibiting β-Catenin by β-Carboline-Type MDM2 Inhibitor for Pancreatic Cancer Therapy
by: Jiang-Jiang Qin, et al.
Published: (2018) -
3-(1,2,3-Triazol-4-yl)-β-Carbolines and 3-(1<i>H</i>-Tetrazol-5-yl)-β-Carbolines: Synthesis and Evaluation as Anticancer Agents
by: João L. P. Ribeiro, et al.
Published: (2022) -
A Small β-Carboline Derivative "B-9-3" Modulates TGF-β Signaling Pathway Causing Tumor Regression in Vivo
by: Hui Zhong, et al.
Published: (2018) -
Anticholinesterase activity of β-carboline-1,3,5-triazine hybrids
by: Paula Baréa, et al.
Published: (2022) -
Current State of Radiolabeled Heterobivalent Peptidic Ligands in Tumor Imaging and Therapy
by: Benedikt Judmann, et al.
Published: (2020)